Relationship of EGFR gene mutation and clinical efficacy of patients with terminal NSCLC treated with gefitinib from Zhoushan

VernacularTitle:吉非替尼治疗晚期非小细胞肺癌合并恶性胸腔积液的疗效及其与表皮生长因子受体基因突变的关系研究
Author: Yan′er SHAO ; Lei ZHOU ;
Publication Type:Journal Article
Keywords: Carcinoma,non -small -cell lung; Protein -tyrosine kinases; Pleural effusion,Malignant; Ge-fitinib
From: Chinese Journal of Primary Medicine and Pharmacy 2015;(12):1774-1775,1776
CountryChina
Language:Chinese
Abstract: Objective To study the relationship of EGFR gene mutation and clinical efficacy of patients with terminal NSCLC treated with gefitinib from Zhoushan.Methods 45 patients with terminal NSCLC were divided into the mutation group and normal group according to EGFR mutation.And all patients were received gefitinib treatment. Clinical efficacy was observed.Results The objective response rate and PFS of the mutation group were 76.92%, (232.8 ±24.3)d;The objective response rate and PFS of the normal group were 31.25%,(156.7 ±26.5)d;The objective response rate of the mutation group was significantly higher than that of the normal group(χ2 =7.810,P <0.05),and the PFS of the mutation group was also significantly higher than that of the normal group(t =5.665,P <0.05).Conclusion EGFR gene mutation patients with terminal NSCLC treated with gefitinib has higher clinical effi-cacy.